[{"orgOrder":0,"company":"LPOXY Therapeutics","sponsor":"5Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LPOXY Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"LPOXY Therapeutics \/ 5Horizons Ventures","highestDevelopmentStatusID":"6","companyTruncated":"LPOXY Therapeutics \/ 5Horizons Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by LPOXY Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The proceeds will fund the registrational STOP-Cdiff (sidiprev trial on prevention of C. difficile infections) trial for Sidiprev, positioned to become the first prevention against C. difficile.

                          Product Name : Sidiprev

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 03, 2025

                          Lead Product(s) : Oxygen

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : 5Horizons Ventures

                          Deal Size : $28.0 million

                          Deal Type : Series A Financing

                          blank